TV Report: Cleveland Biolabs working with Japanese to send doses of radiation antidote Print E-mail
By M.E.Garza   
Wednesday, 16 March 2011 01:09

best penny picksA late breaking television news report from WIVB-TV; a CBS-affiliated television station for Western New York that is licensed to Buffalo is reporting that Cleveland Biolabs (Nasdaq:CBLI) is now working directly with the Japanese government to send a new radiation-protective drug to workers at Japan's nuclear power plants.

Buffalo's Cleveland Biolabs tackling Japan's nuclear crisis: wivb.com

The government of Japan has just suspended operations to prevent the stricken Fukushima Dai-ichi nuclear plant from melting down Wednesday after a surge in radiation forced workers to take cover indoors.The country has ordered a nearby 140,000 people to seal themselves indoors after a series of explosions and fires at the plant. The latest fire, at the plant's No. 4 reactor, is under control, according to TEPCO, which blamed it on an earlier fire that hadn't been fully extinguished. But Japan's nuclear agency was unable to confirm that the blaze had been put out, and clouds of white smoke were billowing from the reactor, according to live video footage of the plant.

Damage to the fuel rods at the No. 1 reactor were at 70 percent. Kyodo News added that 33 percent of the second reactor's fuel rods were also damaged.

The televised news report out of Western New York was followed by a 10:30pm PST report on Clear Channel Radio stations across the U.S. in which Arnie Gundersen, Nuclear Engineer and Safety Expert, of  Fairewinds Association issued the following statement:

NHK TV“I think the Unit 4 firefighters were withdrawn because the fuel pools are drying out. That means high levels of Cesium-137 at the site and the uranium products will turn into radioactive gasses that can touch skin and be breathed in. This is as bad as, or worse than, Chernobyl.”

Other experts, including Scott Portzline, who has kept watch on security issues at Three Mile Island for 25 years, expressed concerns after reportedly spotting a hole in the wall of of Unit # 4 at Fukushima Dai-ichi nuclear power plant in a report from NHK Wortld TV News.

Many are hoping, for the sake of the people of Japan, that these experts are wrong and that their pessimistic predictions are premature.

The deteriorating situation and concerns about a potential shift in wind direction that could send radiation toward populated areas prompted authorities to warn people as far as 18.6 miles from the plant to stay inside.

The plant holds six reactors. About 200,000 people living within a 12.4-mile (20 kilometer) radius of the plant already had been evacuated.

Between Units 3 and 4, Japanese authorities said they had measured radiation dose rates of up to 400 millisieverts-per-hour, IAEA reported. That's equivalent to about 2,000 chest x-rays per hour, the agency said on its website. "This is a high dose-level value, but it is a local value at a single location and at a certain point in time," it added.

Cleveland Biolabs' CBLB502 is a late-stage drug candidate which can be effectively delivered by intramuscular or subcutaneous injection. It is, in essence, a radiation antidote which can efectively protect the human body from stresses of radiation, chemotherapy or high levels of nuclear exposure.

Based on the accelerated review and approval status currently available for drugs qualifying for Fast Track status, the company believes that their most advanced drug candidate, Protectan CBLB502 may be approved for treatment of acute radiation syndrome within a year or so, but management told BioMedReports in an exclusive interview on Tuesday that an Emergency Use Authorization from the governemt of Japan could be granted in order for them to ship any of the thousands of doses which they have available to Japan for use on patients who have been exposed to high levels of radiation.

BioMedReports was the first to report that the company had been in communication with certain U.S. agencies responsible for nuclear counter-measures and that these same agencies were made aware that Cleveland Biolabs had doses of CBLB502 which could be made available for emergency use to Japan.

“Obviously, this has to be tied into some type of approval- probably under emergency use authorization- if they decide to use it,” CEO Michael Fonstein told BMR. “Whatever the Japanese feel they need, they will have to decide for themselves, but we are willing to make a certain number of doses available to them.

“As far as getting into details as to which agencies we have been in contact with, I can only use the term ‘appropriate U.S. agencies,’” explained Fonstein. “At this point I would not be comfortable to be more specific. But we have been speaking through the approriate channels and have actually made them aware that we do have doses available and on-hand.”

Leaks From Japan's Nuclear Plants Could Send Cleveland Biolabs' Shares Beyond $20

CBLI officials in touch with appropriate U.S. agencies as Japan's nuclear reactors remain unstable

Cleveland Biolabs Shares Rising on Japan's Nuclear Meltdown Fears

On Tuesday, the company filed their annual report with the SEC and in it explained that their development efforts are based on discoveries made in connection with the investigation of the cell-level process known as apoptosis. Apoptosis is a highly specific and tightly regulated form of cell death that can occur in response to external events such as exposure to radiation, toxic chemicals or internal stresses. Apoptosis is a major determinant of tissue damage caused by a variety of medical conditions including cerebral stroke, heart attack and acute renal failure. Conversely, apoptosis is also an important protective mechanism that allows the body to shed itself of defective cells, which otherwise can cause cancerous growth.

Research has demonstrated that apoptosis is sometimes suppressed naturally. For example, most cancer cells develop resistance to apoptotic death caused by drugs or natural defenses of the human body. Our research is geared towards identifying the means by which apoptosis can be affected and manipulated depending on the need.

If the need is to protect healthy tissues against an external event such as exposure to radiation, we focus our research efforts on attempting to temporarily and reversibly suppress apoptosis in those healthy tissues, thereby imitating the apoptotic-resistant tendencies displayed by cancer cells. A drug with this effect would also be useful in ameliorating the toxicities of anticancer drugs and radiation that cause collateral damage to healthy tissues during cancer treatment. Because the severe toxicities of anticancer drugs and radiation often limit their dosage in cancer patients, an apoptosis suppressant drug may enable a more aggressive treatment regimen using anticancer drugs and radiation and thereby increase their effectiveness.

The company's Protectans are modified factors of microbes that protect cells from apoptosis, and which therefore have a broad spectrum of potential applications. The potential applications include both non-medical applications such as protection from exposure to radiation, whether as a result of military or terrorist action or as a result of a nuclear accident, as well as medical applications such as reducing cancer treatment toxicities.

In the area of radiation protection, we have achieved high levels of protection in animal models. With respect to cancer treatment, the biology of cancer is such that there is no single drug that can be successfully used to treat a significant proportion of the large number of different cancers and there is wide variability in individual responses to most therapeutic agents. This means there is a continuing need for additional anticancer drugs for most cancers.

BioMedReports began recommending the stock to its subscribers and readers when it was trading in the $3 range. In recent days, shares jumped by 28% since the outbreak of fears of a nuclear catastrophe in northeast Japan. Cleveland’s shares catapulted past the $9 level at one point Tuesday. If some sort of Emergency Use Authorization has indeed been inssued, analysts believe Cleveland Shares could go beyond $20 per share and even higher if the situation with the nuclear power plants in Japan actually leads to a meltdown.

Japan suspended operations to prevent the stricken Fukushima Dai-ichi nuclear plant from melting down Wednesday after a surge in radiation forced workers to take cover indoors.The country has ordered a nearby 140,000 people to seal themselves indoors after a series of explosions and fires at the plant. The latest fire, at the plant's No. 4 reactor, is under control, according to TEPCO, which blamed it on an earlier fire that hadn't been fully extinguished. But Japan's nuclear agency was unable to confirm that the blaze had been put out, and clouds of white smoke were billowing from the reactor, according to live video footage of the plant.

Damage to the fuel rods at the No. 1 reactor were at 70 percent. Kyodo News added that 33 percent of the second reactor's fuel rods were also damaged.

 

Disclosure: Long CBLI



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter